Is MOTS-c Legal in Australia?
A neutral look at MOTS-c, a mitochondrial-derived peptide, and its research-use-only status under Australian regulation, the TGA framework and WADA.
The short answer
MOTS-c is not an approved medicine in Australia. It does not appear on the Australian Register of Therapeutic Goods (ARTG) as a registered or listed therapeutic product, which means it is not authorised for general supply as a medicine for human or animal use. Where MOTS-c is offered in Australia, it is supplied strictly as a research-use-only laboratory compound intended for in-vitro and preclinical investigation by qualified researchers, not for consumption.
This article explains, in neutral terms, what MOTS-c is, how Australia's regulatory framework treats unapproved peptides, and where sport anti-doping rules fit in. It makes no therapeutic, metabolic or performance claims and offers no usage guidance. The aim is to help researchers and interested readers understand the regulatory picture accurately.
What MOTS-c is
MOTS-c (mitochondrial open reading frame of the twelve S ribosomal RNA type-c) is a mitochondrial-derived peptide. It is a short peptide of 16 amino acids encoded within a small open reading frame nested inside the mitochondrial 12S ribosomal RNA (rRNA) region of the mitochondrial genome. It was first described in the scientific literature in 2015.
As a research compound, MOTS-c is studied in laboratory and preclinical settings. It belongs to a broader group of molecules sometimes called mitochondrial-derived peptides. These are the subject of ongoing scientific interest, and the published human clinical evidence remains limited and early-stage.
- Class: mitochondrial-derived peptide
- Length: 16 amino acids
- Encoded within: the mitochondrial 12S rRNA region
- First reported: 2015, in the research literature
- Status: a research compound, not an approved medicine
How Australia regulates therapeutic goods
In Australia, medicines and other therapeutic goods are regulated by the Therapeutic Goods Administration (TGA) under the Therapeutic Goods Act. Products intended for therapeutic use generally must be entered on the ARTG before they can be lawfully imported, advertised or supplied for that purpose. A product that is not on the ARTG is considered unapproved and is not available for general supply as a medicine.
MOTS-c has no ARTG entry. Many peptides, when they are intended for therapeutic use, fall within prescription-only categories of the Poisons Standard (also called the SUSMP), commonly Schedule 4. The specific scheduling of any individual substance can change over time, so the conservative position is to treat MOTS-c as an unapproved substance that is not authorised for general human or animal use.
Research-grade MOTS-c is a different proposition from an approved medicine. It is sold on a research-use-only basis, meaning it is supplied for laboratory and research applications only and is not intended, labelled or promoted for human or animal consumption.
What research-use-only actually means
Research-use-only is a supply and labelling framework, not a loophole for personal use. A compound sold under this framework is intended for in-vitro experiments and preclinical research conducted by people with the appropriate facilities and expertise. It is not a consumer product and carries no therapeutic approval.
Because MOTS-c is an unapproved substance, it cannot be lawfully advertised or supplied as a treatment, supplement or performance product in Australia. Responsible research-use-only suppliers reflect this by avoiding health claims, labelling material clearly for laboratory use, and declining to provide dosing or administration guidance.
- For laboratory and preclinical research by qualified users
- Not for human or animal consumption
- No therapeutic approval and no health claims
- Clearly labelled and handled as a research chemical
MOTS-c and anti-doping rules
Athletes and sporting bodies should be aware that mitochondrial-derived peptides and AMP-activated protein kinase (AMPK) activators have been addressed by anti-doping authorities. MOTS-c has been referenced in connection with the World Anti-Doping Agency (WADA) Prohibited List in the category of metabolic modulators.
Because the WADA Prohibited List is updated regularly and the exact classification and wording can change year to year, anyone involved in sport should consult the current official WADA Prohibited List, and their national anti-doping organisation, rather than relying on a general summary. Substances can be prohibited in and out of competition.
Importing and buying considerations
Importing an unapproved substance into Australia is subject to border and therapeutic goods controls. Because MOTS-c is not ARTG-registered, bringing it into the country can attract regulatory attention, and the conservative assumption is that it is not available for general personal import or supply.
Consumer protection law also applies to how any product is marketed. Suppliers in Australia must not make false or misleading claims, which is another reason reputable research-use-only vendors avoid therapeutic or performance messaging. If you are assessing a supplier or a product, product quality, labelling accuracy and verification of identity all matter.
Where the science currently sits
MOTS-c is an active area of laboratory research, and much of the published work to date has been conducted in cell and animal models. Robust, large-scale human clinical trial data is limited, and the compound has not been approved by Australian or comparable overseas regulators for any medical use.
This early-stage status is one reason the regulatory framing is cautious. Until a substance completes the evidence and approval pathway, it remains an unapproved compound, which is why MOTS-c continues to be handled on a research-use-only basis rather than as a therapeutic product.
Summary
MOTS-c is a 16-amino-acid mitochondrial-derived peptide that is not registered on the ARTG and is not an approved medicine in Australia. It is supplied, where available, strictly as a research-use-only laboratory compound and is not intended for human or animal use.
Unapproved peptides sit outside general supply, often falling within prescription-only scheduling when intended therapeutically, and anti-doping rules may apply in sport. Anyone evaluating MOTS-c should treat it as an unapproved research compound, check the current WADA Prohibited List if sport is involved, and rely on official TGA and WADA sources for the most current position.
Frequently asked questions
Is MOTS-c approved by the TGA?
No. MOTS-c is not entered on the Australian Register of Therapeutic Goods, so it is not an approved medicine and is not authorised for general supply for human or animal use in Australia.
What is MOTS-c?
MOTS-c is a mitochondrial-derived peptide of 16 amino acids, encoded within the mitochondrial 12S rRNA region. It was first reported in the research literature in 2015 and is studied as a research compound.
Can I buy MOTS-c legally in Australia?
Where MOTS-c is offered in Australia it is supplied strictly as a research-use-only laboratory compound, not as a medicine or consumer product. It is unapproved, so it cannot be lawfully advertised or supplied for human or animal use.
Is MOTS-c banned in sport?
Mitochondrial-derived peptides and AMPK activators have been addressed by anti-doping authorities. Because the WADA Prohibited List changes each year, athletes should consult the current official list and their national anti-doping organisation.
Is MOTS-c a prescription substance in Australia?
Many peptides, when intended for therapeutic use, fall within prescription-only categories of the Poisons Standard, commonly Schedule 4. Scheduling can change, so the conservative view is to treat MOTS-c as an unapproved substance not available for general supply.
Has MOTS-c been tested in humans?
Published human clinical data is limited and early-stage. Much of the research to date has been conducted in cell and animal models, and MOTS-c has not been approved by regulators for any medical use.
What does research-use-only mean for MOTS-c?
It means the compound is supplied for laboratory and preclinical research by qualified users only. It is not intended, labelled or promoted for human or animal consumption and carries no therapeutic approval.
This article is general information for research buyers. All Pepology products are supplied strictly for laboratory research use only and are not for human or animal use. Every batch is independently tested by Novagen Laboratories and verifiable on a public register.